Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reisch

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|June 24, 2015
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvirPreethi Krishnan, Rakesh Tripathi, Gretja Schnell, et al.
Plos One|October 5, 2018
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvirGretja Schnell, Preethi Krishnan, Rakesh Tripathi, et al.
Nordic Journal of Psychiatry|February 21, 2013
Serious suicidal behaviors: socio-demographic and clinical features in a multinational, multicenter sampleVladimir Carli, Laura Mandelli, Leonardo Zaninotto, et al.
Antimicrobial Agents and Chemotherapy|December 9, 2015
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and OmbitasvirPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy|August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsPreethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5APreethi Krishnan, Jill Beyer, Neeta Mistry, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Journal of Medical Virology|August 27, 2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavirGretja Schnell, Rakesh Tripathi, Preethi Krishnan, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Tami Pilot-Matias, Rakesh Tripathi, Daniel Cohen, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|June 24, 2015
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvirPreethi Krishnan, Rakesh Tripathi, Gretja Schnell, et al.
Plos One|October 5, 2018
Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvirGretja Schnell, Preethi Krishnan, Rakesh Tripathi, et al.
Nordic Journal of Psychiatry|February 21, 2013
Serious suicidal behaviors: socio-demographic and clinical features in a multinational, multicenter sampleVladimir Carli, Laura Mandelli, Leonardo Zaninotto, et al.
Antimicrobial Agents and Chemotherapy|December 9, 2015
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and OmbitasvirPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy|August 1, 2018
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical TrialsPreethi Krishnan, Tami Pilot-Matias, Gretja Schnell, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5APreethi Krishnan, Jill Beyer, Neeta Mistry, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in JapanPreethi Krishnan, Gretja Schnell, Rakesh Tripathi, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor PibrentasvirTeresa I Ng, Preethi Krishnan, Tami Pilot-Matias, et al.
Journal of Medical Virology|August 27, 2017
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavirGretja Schnell, Rakesh Tripathi, Preethi Krishnan, et al.
Antimicrobial Agents and Chemotherapy|December 3, 2014
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Tami Pilot-Matias, Rakesh Tripathi, Daniel Cohen, et al.
Pageof 5